MADISON, Wis. & BASEL, Switzerland--(BUSINESS WIRE)--Scarab Genomics, a pioneer in the world of E. coli genomics and production strains, and Lonza, a world leader in biopharmaceutical development and production, announced today the companies have entered into a preferred marketing and sales agreement for Scarab Genomics’ Clean Genome® E. coli. Financial details of the contract were not disclosed.
